# Ichnos Glenmark Innovation (IGI) Announces IND Submission to U.S. FDA for ISB 2301, a First-in-Class Multispecific Immune Cell Activator Targeting Solid Tumors

- Published: 2026-11-17
- Author: [Healthcare News](https://healthcarenews.io/author/healthcarenews-io.md)
- Topics: [News](https://healthcarenews.io/news.md)
- Source: https://healthcarenews.io/news/ichnos-glenmark-innovation-igi-announces-ind-submission-to-u-s-fda-for-isb-2301-a-first-in/
- Publication: Healthcare News
- Publisher: Connectively (Terkel, Inc.)
- Editorial policy: https://healthcarenews.io/editorial-policy/

**ISB 2301 targets three tumor-associated antigens (TAAs) and engages both T cells and natural killer (NK) cells**

**IGI plans to initiate a Phase 1 trial evaluating ISB 2301 in patients with solid tumors in 2027**

NEW YORK, Nov. 17, 2026 [(GLOBE NEWSWIRE)](https://www.globenewswire.com) -- Ichnos Glenmark Innovation, Inc. (IGI), a global clinical-stage biotechnology company focused on developing Multispecific™ therapeutics in oncology, today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for ISB 2301.

ISB 2301 is a first-in-class, investigational multispecific immune cell activator designed to target three tumor-associated antigens and engage both T cells and NK cells. This pentaspecific molecule combines five binding specificities: three tumor-associated antigens, plus T-cell and NK-cell activation. By combining tumor-cell recognition with complementary immune activity, ISB 2301 is being developed to address biological heterogeneity and immune-suppressive features of solid tumors.

"Submission of the IND for ISB 2301 marks an important milestone in advancing IGI’s multispecific oncology pipeline into clinical development,” **said Lida Pacaud, M.D., President and Chief Executive Officer, IGI**. “This pentaspecific candidate is designed to integrate multiple tumor-targeting and immune-engaging functions within a single molecule. Our preclinical results have demonstrated a compelling anti-cancer profile for ISB 2301, a candidate we believe to be highly differentiated from current approaches. We plan to initiate a Phase 1 clinical trial of ISB 2301 in patients with solid tumors in 2027.”

ISB 2301 was engineered using IGI’s proprietary BEAT® Multispecific Platform and is designed to recognize three tumor-associated antigens while engaging both T cells and NK cells through complementary mechanisms, including antibody-dependent cellular cytotoxicity (ADCC), checkpoint inhibition, and the induction of a sustained type 1 immune response.

In preclinical studies, ISB 2301 demonstrated favorable pharmacokinetic and tolerability profiles in non-human primates, supporting the planned evaluation of its safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity in patients with advanced solid tumors.

**About IGI**

IGI is a global, fully integrated clinical-stage biotechnology company focused on developing innovative biologics in oncology. Headquartered in New York, NY, IGI is advancing a robust pipeline of novel, first-in-class Multispecifics™ powered by its proprietary BEAT® technology platform. The platform has demonstrated clinical proof of concept through ISB 2001, an investigational CD38 × BCMA × CD3 trispecific T-cell engager that has shown promising anti-tumor activity and favorable safety profile in patients with heavily pretreated relapsed/refractory multiple myeloma in an investigational Phase 1 study. IGI is committed to delivering breakthrough curative therapies to improve and extend the lives of patients battling hematological malignancies and solid tumors. For more information, visit <a href="https://www.globenewswire.com/Tracker?data=SdHc7bPzfsy_afUnimCbNNM4f_RRstSFjqaxziUhiW3EY88oB4RJ7McmcJFkoLakqdW8LV7_fvyttqKy2PCvkp5vmu0bx_AfynLfLRGA8F4=" rel="nofollow">www.IGInnovate.com</a>.

**IGI Corporate Communications:**

<a href="https://www.globenewswire.com/Tracker?data=7RD1o4fTRFMq--Zq5sFKtIyj-_trllVtyUkzfy9HFlI2FJgUUvLblneLaQFtidvt7se3Xw4HEpgYtma9EF0skTVeqnI6l9N44hPdfqgGGyKYx4CjEa7f7qBmeTlZpOuIjjwa6rj2tdoyUOXOwMlJgDPwFIABj_S6aOaf0kzfuoI=" rel="nofollow">Corporate.communications@IGInnovate.com</a>

  
![](https://ml.globenewswire.com/media/ZWQ3YmEwODktNzA0Ni00MzI2LWJkZGYtNTA2MmQ0YTFiOTc3LTUwMDEyNDQ3OC0yMDI2LTExLTE3LWVu/tiny/IGI-Inc-.png)

## Related

- [Myriad Genetics Expands SRL Partnership in Japan to Support Future Growth](https://healthcarenews.io/news/myriad-genetics-expands-srl-partnership-in-japan-to-support-future-growth.md)
- [Integer Announces Completion of Acquisition by KKR](https://healthcarenews.io/news/integer-announces-completion-of-acquisition-by-kkr.md)
- [MAIA Biotechnology Reports Consistent Strong Efficacy in Expanded Phase 2 THIO-101 Study in Non-Small Cell Lung Cancer](https://healthcarenews.io/news/maia-biotechnology-reports-consistent-strong-efficacy-in-expanded-phase-2-thio-101-study-i.md)
- [Gix Deploys New Advanced AI-Powered L4 Autonomous Robot with Multi-Environment Navigation and Smart Access Capabilities at One of the World’s Top Hospitals](https://healthcarenews.io/news/gix-deploys-new-advanced-ai-powered-l4-autonomous-robot-with-multi-environment-navigation.md)
